Today it was reported that a Director at Arbutus Biopharma Corporation (ABUS), Mark J. Murray, exercised options to buy 25,000 ABUS shares at $1.35 a share, for a total transaction value of $33.75K. The options were close to expired and Mark J. Murray retained stocks.
This recent transaction increases Mark J. Murray’s holding in the company by 7.9% to a total of $1.63 million.
See today’s analyst top recommended stocks >>
Currently, Arbutus Biopharma Corporation has an average volume of 243K.
Based on 4 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $6.83, reflecting a 56.7% upside.
Mark J. Murray’s trades have generated a -16.4% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Arbutus Biopharma Corp. is a biopharmaceutical company, engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company was founded on October 6, 2005 and is headquartered in Burnaby, Canada.
